BBIO
BridgeBio Pharma, Inc.
Latest Form 4:Sale$2.9MbyKumar Neil (Chief Executive Officer) · filed Aug 20, 2026
BridgeBio Pharma, Inc. (BBIO) has 63 SEC Form 4 filings (237 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
Inside the rolling window, 10 insiders at BridgeBio Pharma, Inc. reported no open-market purchases and 54 open-market sales totaling $128.1M. The most active filer is Chief Executive Officer Kumar Neil with 26 filings. Insiders have net sold $61.1M over the trailing 6 months. The most recent open-market filing is a sale of 34,980 shares by Chief Executive Officer Kumar Neil, dated Aug 18, 2026, worth $2.9M.
- Industry:Biotechnology
- CEO:Neil Kumar
- Employees:725
- HQ:Palo Alto, CA, US
- IPO:2019-06-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$128.1M
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Market Cap
$15.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 34,980 | $2.9M | Aug 20 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $840K | Aug 20 | SEC ↗ | |
Apuli MaricelFirst in 3 months | Chief Accounting Officer | Sale | 2,000 | $160K | Aug 3 | SEC ↗ |
Ellis AndreaFirst in 4 months | Director | Sale | 17,167 | $1.4M | Jul 13 | SEC ↗ |
| Director | Sale | 148,589 | $13.2M | Jul 13 | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | SEC ↗ | |
| Director | Sale | 37,167 | $2.6M | Jun 24 | SEC ↗ | |
| Director | Sale | 2,808 | $191K | Jun 24 | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | SEC ↗ | |
Cook Jennifer E.First filing | Director | Sale | 90,240 | $6.0M | Jun 17 | SEC ↗ |
| Chief Executive Officer | Sale | 35,921 | $2.4M | Jun 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 31,563 | $2.1M | Jun 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 26,103 | $1.8M | May 26 | SEC ↗ | |
Scott Randal W.First in 3 months | Director | Sale | 10,000 | $671K | May 19 | SEC ↗ |
Trimarchi ThomasFirst in 3 months | President and CFO | Sale | 13,651 | $888K | May 19 | SEC ↗ |
| Chief Executive Officer | Sale | 40,000 | $2.7M | May 11 | SEC ↗ | |
| Chief Executive Officer | Sale | 39,050 | $2.6M | May 11 | SEC ↗ | |
| Chief Accounting Officer | Sale | 2,000 | $143K | May 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Apr 13 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Apr 13 | SEC ↗ | |
| Chief Executive Officer | Sale | 39,700 | $2.7M | Mar 16 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.8M | Mar 16 | SEC ↗ | |
| Director | Sale | 8,671 | $624K | Mar 12 | SEC ↗ | |
Ellis AndreaFirst filing | Director | Sale | 64,921 | $4.2M | Mar 6 | SEC ↗ |
Valantine HannahFirst in 4 months | Director | Sale | 25,484 | $1.7M | Mar 3 | SEC ↗ |
| Chief Accounting Officer | Sale | 2,000 | $132K | Feb 27 | SEC ↗ | |
| Chief Executive Officer | Sale | 28,053 | $2.0M | Feb 23 | SEC ↗ | |
Scott Randal W.First in 3 months | Director | Sale | 10,000 | $755K | Feb 18 | SEC ↗ |
Trimarchi ThomasFirst in 3 months | President and CFO | Sale | 13,600 | $1.0M | Feb 18 | SEC ↗ |
| Chief Accounting Officer | Sale | 510 | $38K | Feb 18 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.9M | Feb 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.9M | Feb 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Jan 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.1M | Jan 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 30,011 | $2.2M | Dec 16 | SEC ↗ | |
Apuli MaricelFirst filing | Chief Accounting Officer | Sale | 2,000 | $149K | Dec 10 | SEC ↗ |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Dec 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.9M | Dec 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 26,156 | $1.7M | Nov 24 | SEC ↗ | |
Lo AndrewFirst filing | Director | Sale | 40,599 | $2.7M | Nov 19 | SEC ↗ |
Lo AndrewFirst filing | Director | Sale | 55,000 | $3.6M | Nov 19 | SEC ↗ |
Scott Randal W.First filing | Director | Sale | 10,000 | $666K | Nov 19 | SEC ↗ |
Trimarchi ThomasFirst filing | President and CFO | Sale | 16,934 | $1.1M | Nov 18 | SEC ↗ |
Valantine HannahFirst filing | Director | Sale | 25,484 | $1.7M | Nov 14 | SEC ↗ |
| Chief Executive Officer | Sale | 39,900 | $2.5M | Nov 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.5M | Nov 10 | SEC ↗ | |
DANIELS RONALD JFirst filing | Director | Sale | 61,031 | $3.9M | Nov 7 | SEC ↗ |
| Director | Sale | 198,359 | $13.2M | Oct 31 | SEC ↗ | |
| Director | Sale | 1,641 | $107K | Oct 29 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.2M | Oct 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.1M | Oct 10 | SEC ↗ | |
Kumar NeilFirst filing | Chief Executive Officer | Sale | 40,000 | $2.1M | Sep 8 | SEC ↗ |
Kumar NeilFirst filing | Chief Executive Officer | Sale | 40,000 | $2.1M | Sep 8 | SEC ↗ |
MCCORMICK FRANKFirst filing | Director | Sale | 74,000 | $3.9M | Sep 8 | SEC ↗ |
Congress trading BBIO
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-11
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does BBIO have?
BridgeBio Pharma, Inc. (BBIO) has 63 SEC Form 4 filings (237 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
When was the most recent SEC Form 4 filing for BBIO?
The most recent Form 4 filing for BBIO on Tracefour is dated Aug 20, 2026.
Who is the most active insider at BBIO?
The most active SEC Form 4 filer at BBIO in the rolling window is Chief Executive Officer Kumar Neil, with 26 filings.
What is the net insider flow at BBIO over the last 6 months?
Over the trailing 180 days, insiders at BBIO have net sold $61.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at BBIO in the current window?
Inside the rolling window, insiders at BBIO bought $0 and sold $128.1M based on SEC Form 4 filings.
Can I get alerts for BBIO insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at BridgeBio Pharma, Inc. (BBIO). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
BridgeBio Pharma, Inc. is in the Healthcare sector.